Novo Nordisk A/s

Innate Pharma S.a.s.

Novo Nordisk-a/s Novo Alle

University of Genoa

Innate Pharma

Universita Di Genova

Ivan Svendsen

Peter Andreas Nicolai Reumert Wagtmann

Alessandro Moretta

Pascale Andre

Kristian Kjaergaard

Stefan Zahn

Anders Svensson

Mariella Della Chiesa

Laurent Gauthier

Francois Romagne

Rune Viig Overgaard

Lene Hjorth Alifrangis

Matthias Thorolfsson

Michael Wilken

Rozana Sten

Søren Berg Padkær

Soren Berg Padkjaer

Pieter Spee

Francois Romagné

Soren Berg Padkaer

Pieter Johannes Louis Spee

Laurant Gauthier

Petrus Johannes Loius Spee

Milchael Wilken

Matthias Thórólfsson

Rozana Svensson

Søren Berg Padkaer

A novel IgG4 isotype anti-KIR antibody, novel formulations of this and other IgG4 anti-KIR antibodies, and methods of using such formulations are provided. Also described are compositions, formulations, dosages, and administration regimens suitable for NK cell activation and therapeutic applications of anti-KIR antibodies, as well as kits comprising one or more anti-KIR antibodies with instructions for use in treating cancer.

Anti-KIR antibodies, formulations, and uses thereof

Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Human anti-KIR antibodies

Nucleic acids encoding human anti-kir antibodies

Growing community of inventors

Smorum, Denmark

Ivan Svendsen